Option chain shows key data for Corix Bioscience's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Corix Bioscience.

Corix Bioscience (OTC:CXBS) Stock, Option Chain

Corix Bioscience Inc is a United States-based research and development firm of cannabidiol (CBD) products and treatments. It is engaged in the business of producing organic CBD oil used for medical applications and treatments. In addition, the group is also focused on the production of tetrahydrocannabivarin oil. The company is focused on operations in Oregon, California, and Nevada, United States.

CORIX BIOSCIENCE INC by Corix Bioscience, Inc.

Corix Bioscience Inc

The Company expects organic sales growth to be within its long-term targeted range of 3% to 5%, including the impact of the planned exit from private label pet nutrition over the course of 2025.
On a GAAP basis, the Company expects gross profit margin expansion with advertising investment flat to up slightly on both a dollar basis and as a percent to sales and mid-single-digit earnings-per-share growth.
On a non-GAAP (Base Business) basis, the Company expects gross profit margin expansion with advertising investment flat to up slightly on both a dollar basis and as a percent to sales and low to mid-single-digit earnings-per-share growth.

News

Guidance

Based On Current Spot Rates, Colgate-Palmolive Expects FY25 Net Sales To Be Roughly Flat, Including Mid-Single-Digit Negative Impact From Foreign Exchange

Church &amp; Dwight Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHD#NYSE">CHD</a>) reported quarterly adjusted earnings of $0.77 per share which met the analyst consensus estimate. This is a 18.46 percent increase over earnings of $0.65 per share from the same period last year. The company reported quarterly sales of $1.58 billion which beat the analyst consensus estimate of $1.56 billion by 1.12 percent. This is a 3.53 percent increase over sales of $1.53 billion the same period last year.

Earnings

Earnings Beats

Church & Dwight Co Q4 Adj $0.77, Inline, Sales $1.58B Beat $1.56B Estimate

Colgate-Palmolive (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CL#NYSE">CL</a>) reported quarterly earnings of $0.91 per share which beat the analyst consensus estimate of $0.89 by 2.25 percent. This is a 4.6 percent increase over earnings of $0.87 per share from the same period last year. The company reported quarterly sales of $4.94 billion which missed the analyst consensus estimate of $4.98 billion by 0.71 percent. This is a 0.12 percent decrease over sales of $4.95 billion the same period last year.

Earnings Misses

Colgate-Palmolive Q4 2024 Adj EPS $0.91 Beats $0.89 Estimate, Sales $4.94B Miss $4.98B Estimate

KLAC MOVES UP OVER 16 POINTS
<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="749" height="632" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/01/31014119/Screen-Shot-2025-01-30-at-8.40.10-PM.png" alt="" class="wp-image-5205" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/01/31014119/Screen-Shot-2025-01-30-at-8.40.10-PM.png 749w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/01/31014119/Screen-Shot-2025-01-30-at-8.40.10-PM-300x253.png 300w" sizes="(max-width: 749px) 100vw, 749px" /></figure>
KLA Inc. (KLAC) today experienced a Power Inflow, a significant event for those who follow where smart money goes and value order flow analytics in their trading decisions.&nbsp;
Today, at 10:18 AM on January 30th, a significant trading signal occurred for KLA, Inc. (KLAC) as it demonstrated a Power Inflow at a price of $729.93. This indicator is crucial for traders who want to know directionally where institutions and so-called "smart money" moves in the market. They see the value of utilizing order flow analytics to guide their trading decisions. The Power Inflow points to a possible uptrend in KLA&#8217;s stock, marking a potential entry point for traders looking to capitalize on the expected upward movement. Traders with this signal closely watch for sustained momentum in KLA&#8217;s stock price, interpreting this event as a bullish sign.
Signal description
Order flow analytics, aka transaction or market flow analysis, separate and study both the retail and institutional volume rate of orders (flow). It involves analyzing the flow of buy and sell orders, along with size, timing, and other associated characteristics and patterns, to gain insights and make more informed trading decisions. This particular indicator is interpreted as a bullish signal by active traders.&nbsp;
The Power Inflow occurs within the first two hours of the market open and generally signals the trend that helps gauge the stock&#8217;s overall direction, powered by institutional activity in the stock, for the remainder of the day.&nbsp;
By incorporating order flow analytics into their trading strategies, market participants can better interpret market conditions, identify trading opportunities, and potentially improve their trading performance. But let's not forget that while watching smart money flow can provide valuable insights, it is crucial to incorporate effective risk management strategies to protect capital and mitigate potential losses. Employing a consistent and effective risk management plan helps traders navigate the uncertainties of the market in a more controlled and calculated manner, increasing the likelihood of long-term success
If you want to stay updated on the latest options trades for KLAC, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.&nbsp;
<a href="https://benzinga.com/apis?_gl=1&#x2A;1hlgn5i&#x2A;_ga&#x2A;MTY1NjE2NTYxMi4xNzE0NzQ4MTAy&#x2A;_ga_V7ZK73W7N0&#x2A;MTcxNDc0ODEwMi4xLjEuMTcxNDc0ODQyOC4wLjAuMA..">Market News and Data brought to you by Benzinga APIs</a> and include firms, like&nbsp; &nbsp; <a href="https://www.tradepulse.net">https://www.tradepulse.net</a>&nbsp; which are responsible for parts of the data within this article. 
&#xA9; 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
After Market Close UPDATE:
The price at the time of the Power Inflow was $729.93. The returns on the High price ($745.98) and Close price ($743.03) after the Power Inflow were respectively 2.2% and 1.8%. That is why it is important to have a trading plan that includes Profit Targets and Stop Losses that reflect your risk appetite. In this case, the high of the day and close were very close but that is not always the case
Past Performance is Not Indicative of Future Results

Equities

Technicals

TRADEPULSE POWER INFLOW ALERT: KLA CORP., KLAC, RISES OVER 2 % AFTER POWER INFLOW ALERT FROM TRADEPULSE

Booz Allen Hamilton Sees FY25 Revenue Growth Of 12.0%-13.0% (Prior 11%-13%), Adj EBITDA Of $1.31B-$1.33B (Prior $1.30B-$1.33B), Adj EPS Of $6.25-$6.40 (Prior $6.10-$6.30) Vs. $6.30 Est

The earnings results for TDK (OTC:<a class="ticker" href="https://www.benzinga.com/stock/TTDKY#OTC">TTDKY</a>) for Q3 were made public on Friday, January 31, 2025 at 03:00 AM.
Here's a comprehensive overview of the announcement.
<h3>Earnings</h3>
TDK beat estimated earnings by 6.0%, reporting an EPS of $0.19 versus an estimate of $0.18.
Revenue was up $29.00 million from the same period last year.
<h3>Previous Earnings Records</h3>
The company beat on EPS by $0.17 in the previous quarter, leading to a 4.0% increase share price change the next day.
Here's a look at TDK's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2025</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.20</td>
<td>0.10</td>
<td>0.04</td>
<td>0.15</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.37</td>
<td>0.22</td>
<td>0.02</td>
<td>0.23</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>3.98B</td>
<td>3.19B</td>
<td>3.23B</td>
<td>3.84B</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>3.83B</td>
<td>3.33B</td>
<td>3.27B</td>
<td>3.79B</td>
</tr>
</tbody>
</table>

To track all earnings releases for TDK <a href="https://www.benzinga.com/quote/TTDKY/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

TTDKY

Recap: TDK Q3 Earnings

Toyota Motor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TM#NYSE">TM</a>) retained its position as the world&#8217;s best-selling automaker in 2024 after reporting 10.8 million sales, marking a dip of 4% from a year ago. 
What Happened: The dip in sales, the company said, was spurred by a near 20% fall in sales within its home ground of Japan. Domestic vehicle sales, it said, were affected by certification issues and suspension of production of the Prius. 
The sales numbers include those of the company&#8217;s Lexus brand as well as its subsidiaries Daihatsu and Hino. Daihatsu reported sales of 536,588 units worldwide in 2024 while Hino reported sales of 125,556 units. 
German automaker Volkswagen Group, in comparison, sold only about 9 million vehicles last year.
Toyota Trails Behind Tesla In EV Sales: Despite retaining its position as the top-selling automaker globally for five straight years, Toyota&#8217;s electrified vehicle sales amounted to just 4.5 million vehicles in 2024. Electrified vehicles refer collectively to <a href="https://www.benzinga.com/tech/25/01/42809131/toyota-overtakes-ford-gm-in-ev-sales-in-us-thanks-to-its-hybrid-vehicle-lineup">hybrid, plug-hybrid</a>, battery-powered, mild hybrid, and fuel-cell electric vehicles. 
The company sold only 139,892 battery electric vehicles or pure electric vehicles throughout the year, lower than American EV giant Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) or Chinese EV maker BYD Co. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BYDDF#OTC">BYDDF</a>).
Tesla delivered nearly<a href="https://www.benzinga.com/25/01/42780142/chinese-player-byd-overtakes-tesla-yet-again-as-worlds-biggest-ev-seller-in-q4"> 1.79 million BEVs in 2024</a> while BYD delivered 1.76 million pure electric vehicles. 
Check out more of Benzinga&#8217;s Future Of Mobility coverage by&nbsp;<a href="https://www.benzinga.com/topic/mobility" target="_blank" rel="noreferrer noopener">following this link.</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/01/43375903/tesla-researcher-estimates-drop-in-ev-deliveries-for-2025-despite-promise-of-new-models" target="_blank" rel="noreferrer noopener">Tesla Researcher Predicts Drop In Deliveries For Elon Musk's EV Giant In 2025 Despite New Model Launches</a></li>
</ul>
Photo by josefkubes on Shutterstock

Tech

BYDDF

TSLA

Toyota Retains Top-Selling Automaker Position While Continuing to Trail Tesla, BYD In EV Sales

The European Commission (EC), which has the authority to approve medicines for the European Union (EU), will now review the CHMP recommendation.

Bristol Myers Squibb Gets Positive CHMP Opinion For CAR T Cell Therapy Breyanzi For Relapsed Or Refractory Follicular Lymphoma

The earnings results for TDK (OTC:<a class="ticker" href="https://www.benzinga.com/stock/TTDKY#OTC">TTDKY</a>) for Q3 were made public on Friday, January 31, 2025 at 03:00 AM.
Here's a comprehensive overview of the announcement.
<h3>Earnings</h3>
TDK beat estimated earnings by 6.0%, reporting an EPS of $0.19 versus an estimate of $0.18.
Revenue was up $29.00 million from the same period last year.
<h3>Historical Earnings Summary</h3>
Last quarter the company beat on EPS by $0.17 which was followed by a 4.0% increase in the share price the next day.
Here's a look at TDK's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2025</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.20</td>
<td>0.10</td>
<td>0.04</td>
<td>0.15</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.37</td>
<td>0.22</td>
<td>0.02</td>
<td>0.23</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>3.98B</td>
<td>3.19B</td>
<td>3.23B</td>
<td>3.84B</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>3.83B</td>
<td>3.33B</td>
<td>3.27B</td>
<td>3.79B</td>
</tr>
</tbody>
</table>

To track all earnings releases for TDK <a href="https://www.benzinga.com/quote/TTDKY/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings Breakdown: TDK Q3

The&nbsp;&nbsp;&nbsp;&nbsp;Company&nbsp;&nbsp;&nbsp;&nbsp;declared&nbsp;&nbsp;&nbsp;&nbsp;a&nbsp;&nbsp;&nbsp;&nbsp;regular&nbsp;&nbsp;&nbsp;&nbsp;quarterly&nbsp;&nbsp;&nbsp;&nbsp;dividend&nbsp;&nbsp;&nbsp;&nbsp;of&nbsp;&nbsp;&nbsp;&nbsp;$0.55&nbsp;&nbsp;&nbsp;&nbsp;per&nbsp;&nbsp;&nbsp;&nbsp;share,&nbsp;&nbsp;&nbsp;&nbsp;an&nbsp;&nbsp;&nbsp;&nbsp;increase&nbsp;&nbsp;&nbsp;&nbsp;of&nbsp;&nbsp;&nbsp;&nbsp;7.8&nbsp;&nbsp;&nbsp;&nbsp;percent,&nbsp;&nbsp;&nbsp;&nbsp;which&nbsp;&nbsp;&nbsp;&nbsp;is&nbsp;&nbsp;&nbsp;&nbsp;payable&nbsp;&nbsp;&nbsp;&nbsp;on&nbsp;&nbsp;&nbsp;&nbsp;March&nbsp;&nbsp;&nbsp;&nbsp;4,&nbsp;&nbsp;&nbsp;&nbsp;2025&nbsp;&nbsp;&nbsp;&nbsp;to&nbsp;&nbsp;&nbsp;&nbsp;stockholders&nbsp;&nbsp;&nbsp;&nbsp;of&nbsp;&nbsp;&nbsp;&nbsp;record&nbsp;&nbsp;&nbsp;&nbsp;on&nbsp;&nbsp;&nbsp;&nbsp;February&nbsp;&nbsp;&nbsp;&nbsp;14,&nbsp;&nbsp;&nbsp;&nbsp;2025.&nbsp;&nbsp;&nbsp;&nbsp;

Dividends

Booz Allen Hamilton Declared A QUarterly Dividend Per Share Of $0.55, Up By 7.8%

Brookfield Bus Partners (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBU#NYSE">BBU</a>) reported $7.427 billion in sales this quarter. This is a 44.60 percent decrease over sales of $13.405 billion the same period last year.

Brookfield Bus Partners Q4 Sales $7.427B Down From $13.405B YoY

Needham analyst Ryan Koontz maintains Calix (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CALX#NYSE">CALX</a>) with a Buy and raises the price target from $45 to $53.

Price Target

Analyst Ratings

CALX

Needham Maintains Buy on Calix, Raises Price Target to $53

Needham analyst Quinn Bolton reiterates Allegro Microsystems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALGM#NASDAQ">ALGM</a>) with a Buy and maintains $30 price target.

Reiteration

ALGM

Needham Reiterates Buy on Allegro Microsystems, Maintains $30 Price Target

Booz Allen Hamilton Q3 2025 Adj. EPS $1.55 Beats $1.51 Estimate, Sales $2.917B Beat $2.864B Estimate

Merck Says Committee For Medicinal Products For Human Use Of The European Medicines Agency Recommended The Approval Of CAPVAXIVE For Active Immunization Of Invasive Disease And Pneumonia Caused By Streptococcus Pneumoniae

TDK (OTC:<a class="ticker" href="https://www.benzinga.com/stock/TTDKY#OTC">TTDKY</a>) reported its Q3 earnings results on Friday, January 31, 2025 at 03:00 AM.
Here's what investors need to know about the announcement.
<h3>Earnings</h3>
TDK beat estimated earnings by 6.0%, reporting an EPS of $0.19 versus an estimate of $0.18.
Revenue was up $29.00 million from the same period last year.
<h3>Overview of Past Earnings</h3>
Last quarter the company beat on EPS by $0.17 which was followed by a 4.0% increase in the share price the next day.
Here's a look at TDK's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2025</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.20</td>
<td>0.10</td>
<td>0.04</td>
<td>0.15</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.37</td>
<td>0.22</td>
<td>0.02</td>
<td>0.23</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>3.98B</td>
<td>3.19B</td>
<td>3.23B</td>
<td>3.84B</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>3.83B</td>
<td>3.33B</td>
<td>3.27B</td>
<td>3.79B</td>
</tr>
</tbody>
</table>

To track all earnings releases for TDK <a href="https://www.benzinga.com/quote/TTDKY/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

TDK Q3 Earnings Assessment

Evercore ISI Group analyst James Kammert initiates coverage on NNN REIT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NNN#NYSE">NNN</a>) with a In-Line rating and announces Price Target of $42.

Initiation

Evercore ISI Group Initiates Coverage On NNN REIT with In-Line Rating, Announces Price Target of $42

Fujitsu (OTC:<a class="ticker" href="https://www.benzinga.com/stock/FJTSY#OTC">FJTSY</a>) lowers FY2024 GAAP EPS guidance from $0.77 to $0.76. Lowers FY2024 sales outlook from $25.26 billion to $22.78 billion.

FJTSY

Fujitsu Lowers FY2024 GAAP EPS Guidance from $0.77 to $0.76; Lowers FY2024 Sales Guidance from $25.26B to $22.78B

WIIM

Signing Day Sports shares are trading higher after the company announced it retains rights as the National Recruiting Partner to the U.S. Army Bowl through 2026 in new deal.

Fujitsu (OTC:<a class="ticker" href="https://www.benzinga.com/stock/FJTSY#OTC">FJTSY</a>) lowers FY2024 Adj EPS guidance from $0.82 to $0.81. sees Adj sales of $22.784 billion.

Comments

Corix Bioscience

Corix Bioscience (CXBS) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga